These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26840144)

  • 1. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
    Borghaei H; Brahmer J
    N Engl J Med; 2016 Feb; 374(5):493-4. PubMed ID: 26840144
    [No Abstract]   [Full Text] [Related]  

  • 2. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
    Hasegawa T; Uno H; Wei LJ
    N Engl J Med; 2016 Feb; 374(5):492-3. PubMed ID: 26840145
    [No Abstract]   [Full Text] [Related]  

  • 3. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
    Gyawali B; Ota A; Ando Y
    N Engl J Med; 2016 Feb; 374(5):493. PubMed ID: 26840146
    [No Abstract]   [Full Text] [Related]  

  • 4. Nivolumab--an effective second-line treatment for NSCLC.
    Romero D
    Nat Rev Clin Oncol; 2015 Dec; 12(12):685. PubMed ID: 26483299
    [No Abstract]   [Full Text] [Related]  

  • 5. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
    Horn L; Spigel DR; Vokes EE; Holgado E; Ready N; Steins M; Poddubskaya E; Borghaei H; Felip E; Paz-Ares L; Pluzanski A; Reckamp KL; Burgio MA; Kohlhäeufl M; Waterhouse D; Barlesi F; Antonia S; Arrieta O; Fayette J; Crinò L; Rizvi N; Reck M; Hellmann MD; Geese WJ; Li A; Blackwood-Chirchir A; Healey D; Brahmer J; Eberhardt WEE
    J Clin Oncol; 2017 Dec; 35(35):3924-3933. PubMed ID: 29023213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung cancer: Squiring immunotherapy to CheckMate.
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Aug; 12(8):436. PubMed ID: 26122186
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice.
    Calpe-Armero P; Ferriols-Lisart R; Ferriols-Lisart F; Pérez-Pitarch A
    Chemotherapy; 2017; 62(6):374-380. PubMed ID: 29045938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Not Available].
    Moro-Sibilot D; Ferrer L; Levra MG; Toffart AC
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S12-5. PubMed ID: 27494968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study.
    Ulmeanu R; Antohe I; Anisie E; Antoniu S
    Expert Rev Anticancer Ther; 2016; 16(2):165-7. PubMed ID: 26634873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
    Ettinger DS; Wood DE; Akerley W; Bazhenova LA; Borghaei H; Camidge DR; Cheney RT; Chirieac LR; D'Amico TA; Dilling TJ; Dobelbower MC; Govindan R; Hennon M; Horn L; Jahan TM; Komaki R; Lackner RP; Lanuti M; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Patel JD; Pisters KM; Reckamp K; Riely GJ; Schild SE; Shapiro TA; Sharma N; Stevenson J; Swanson SJ; Tauer K; Yang SC; Gregory K; Hughes M
    J Natl Compr Canc Netw; 2016 Mar; 14(3):255-64. PubMed ID: 26957612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
    Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
    N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
    Feng Y; Wang X; Bajaj G; Agrawal S; Bello A; Lestini B; Finckenstein FG; Park JS; Roy A
    Clin Cancer Res; 2017 Sep; 23(18):5394-5405. PubMed ID: 28916617
    [No Abstract]   [Full Text] [Related]  

  • 14. A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.
    Matter-Walstra K; Schwenkglenks M; Aebi S; Dedes K; Diebold J; Pietrini M; Klingbiel D; von Moos R; Gautschi O;
    J Thorac Oncol; 2016 Nov; 11(11):1846-1855. PubMed ID: 27311996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab extends survival for patients with nonsquamous non-small-cell lung cancer.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2005 Mar; 6(5):267-8. PubMed ID: 15845175
    [No Abstract]   [Full Text] [Related]  

  • 16. The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma.
    Thornton Snider J; Batt K; Wu Y; Tebeka MG; Seabury S
    Am J Manag Care; 2017 Oct; 23(10):e340-e346. PubMed ID: 29087638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab for advanced squamous cell lung cancer: what are the next steps?
    de Mello RA; Pousa I; Pereira D
    Lancet Oncol; 2015 Mar; 16(3):234-5. PubMed ID: 25704436
    [No Abstract]   [Full Text] [Related]  

  • 18. Prior radiotherapy does not predict nivolumab response in non-small-cell lung cancer: a retrospective cohort study.
    Kataoka Y; Ebi N; Fujimoto D; Hara S; Hirano K; Narabayashi T; Tanaka T; Tomii K; Yoshioka H
    Ann Oncol; 2017 Jun; 28(6):1402. PubMed ID: 28368440
    [No Abstract]   [Full Text] [Related]  

  • 19. Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non-Small Cell Lung Cancer.
    Furuta H; Yoshida T; Shimizu J; Tomita N; Yatabe Y; Hida T
    J Thorac Oncol; 2017 Nov; 12(11):1733-1736. PubMed ID: 28774862
    [No Abstract]   [Full Text] [Related]  

  • 20. Balancing Benefit, Risk, and Time to New Cancer Therapies.
    West HJ
    JAMA Oncol; 2016 Jan; 2(1):122. PubMed ID: 26468768
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.